Nuveen Asset Management LLC Reduces Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Nuveen Asset Management LLC decreased its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 22.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 179,200 shares of the company's stock after selling 50,790 shares during the period. Nuveen Asset Management LLC owned about 0.39% of Omnicell worth $7,978,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its holdings in shares of Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after buying an additional 273 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in Omnicell by 6.9% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock valued at $213,000 after purchasing an additional 307 shares in the last quarter. Van ECK Associates Corp grew its holdings in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after purchasing an additional 315 shares during the period. First Horizon Advisors Inc. grew its holdings in Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after purchasing an additional 355 shares during the period. Finally, Redmond Asset Management LLC increased its position in Omnicell by 0.3% in the fourth quarter. Redmond Asset Management LLC now owns 121,209 shares of the company's stock worth $5,396,000 after buying an additional 371 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Stock Performance

Shares of OMCL stock traded up $0.39 during trading hours on Friday, hitting $30.22. The company's stock had a trading volume of 756,716 shares, compared to its average volume of 568,860. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The company has a 50 day moving average of $30.51 and a 200 day moving average of $38.21. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.75. The stock has a market cap of $1.42 billion, a PE ratio of 111.93, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The company had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. During the same period in the previous year, the company posted $0.03 earnings per share. Omnicell's revenue for the quarter was up 9.5% on a year-over-year basis. On average, sell-side analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Wall Street Zen raised Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, May 20th. JPMorgan Chase & Co. decreased their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Benchmark dropped their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Finally, Bank of America upped their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Omnicell has an average rating of "Moderate Buy" and a consensus target price of $44.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.